On supergravity theories, after ∼ 40 years

An introduction to and a partial review of supergravity theories is given, insisting on concepts and on some important technical aspects. Topics covered include elements of global supersymmetry, a derivation of the simplest N = 1 supergravity theory, a discussion of N =1 matter-supergravity couplings, of the scalar sector and of some simple models. Space-time is four-dimensional.

Testing the Weak Equivalence Principle with an antimatter beam at CERN

The goal of the AEgIS experiment is to measure the gravitational acceleration of antihydrogen – the simplest atom consisting entirely of antimatter – with the ultimate precision of 1%. We plan to verify the Weak Equivalence Principle (WEP), one of the fundamental laws of nature, with an antimatter beam. The experiment consists of a positron accumulator, an antiproton trap and a Stark accelerator in a solenoidal magnetic field to form and accelerate a pulsed beam of antihydrogen atoms towards a free-fall detector. The antihydrogen beam passes through a moir ́e deflectometer to measure the vertical displacement due to the gravitational force. A position and time sensitive hybrid detector registers the annihilation points of the antihydrogen atoms and their time-of-flight. The detection principle has been successfully tested with antiprotons and a miniature moir ́e deflectometer coupled to a nuclear emulsion detector.

The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients

The success of combination antiretroviral therapy is limited by the evolutionary escape dynamics of HIV-1. We used Isotonic Conjunctive Bayesian Networks (I-CBNs), a class of probabilistic graphical models, to describe this process. We employed partial order constraints among viral resistance mutations, which give rise to a limited set of mutational pathways, and we modeled phenotypic drug resistance as monotonically increasing along any escape pathway. Using this model, the individualized genetic barrier (IGB) to each drug is derived as the probability of the virus not acquiring additional mutations that confer resistance. Drug-specific IGBs were combined to obtain the IGB to an entire regimen, which quantifies the virus' genetic potential for developing drug resistance under combination therapy. The IGB was tested as a predictor of therapeutic outcome using between 2,185 and 2,631 treatment change episodes of subtype B infected patients from the Swiss HIV Cohort Study Database, a large observational cohort. Using logistic regression, significant univariate predictors included most of the 18 drugs and single-drug IGBs, the IGB to the entire regimen, the expert rules-based genotypic susceptibility score (GSS), several individual mutations, and the peak viral load before treatment change. In the multivariate analysis, the only genotype-derived variables that remained significantly associated with virological success were GSS and, with 10-fold stronger association, IGB to regimen. When predicting suppression of viral load below 400 cps/ml, IGB outperformed GSS and also improved GSS-containing predictors significantly, but the difference was not significant for suppression below 50 cps/ml. Thus, the IGB to regimen is a novel data-derived predictor of treatment outcome that has potential to improve the interpretation of genotypic drug resistance tests.